Leucid Bio provides business update and outlook for 2023
Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products.Lead programme, LEU011 has completed
Source: finanznachrichten.de